Scarica l'app Stockscreener
18.10
3.62%
-0.6707
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$18.77
Aprire:
$18.765
Volume 24 ore:
2.09M
Relative Volume:
0.96
Capitalizzazione di mercato:
$1.28B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-7.8693
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+14.71%
1M Prestazione:
+14.06%
6M Prestazione:
-67.63%
1 anno Prestazione:
-57.27%
Intervallo 1D:
$17.78
$19.49
Intervallo di 1 settimana:
$15.78
$19.49
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.13 | 1.33B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.75 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.78 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.95 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-15 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-11-03 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy, safety, and financial runway - TradingView
MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data ReleaseHas The Bull Case Changed? - simplywall.st
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy and safety data - TradingView
MoonLake's sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx - European Biotechnology Magazine
Why Is MoonLake Immunotherapeutics Stock Trading Higher TodayMoonLake (NASDAQ:MLTX) - Benzinga
MoonLake stock surges on positive axSpA trial data By Investing.com - Investing.com India
MoonLake stock surges on positive axSpA trial data - Investing.com
MoonLake stock surges 63% after InvestingPro Fair Value call By Investing.com - Investing.com Canada
US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris - Bloomberg.com
MoonLake Highlights Positive S-OLARIS Data and Investor Day - TipRanks
MoonLake arthritis win kicks off pivotal year for IL-17 nanobody - Fierce Biotech
MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study - marketscreener.com
Swiss biotech MoonLake unveils good trial results and strong cash position - Business Weekly
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown - Stocktwits
MoonLake announces results from Phase 2 trial of Sonelokimab - TipRanks
MoonLake reports positive phase 2 axial spondyloarthritis data By Investing.com - Investing.com Australia
MoonLake reports positive phase 2 axial spondyloarthritis data - Investing.com
MoonLake Immunotherapeutics Reports Promising Phase 2 Results for Sonelokimab in Axial Spondyloarthritis and Financial Updates - Quiver Quantitative
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results - The Manila Times
MoonLake Announces Positive Topline Results from its Phase - GlobeNewswire
Biotechnology company MoonLake Immunotherapeutics announced that its innovative drug Sonelokimab achieved positive topline results in a Phase II clinical trial for axial spondyloarthritis. - Bitget
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX - MarketBeat
What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 Levels & Growth Focused Stock Reports - mfd.ru
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits
MoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.5%Still a Buy? - MarketBeat
MoonLake Immunotherapeutics (MLTX) Stock Analysis: A 25% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Price-Driven Insight from (MLTX) for Rule-Based Strategy - Stock Traders Daily
Will MoonLake Immunotherapeutics announce a stock splitWeekly Trade Recap & Capital Protection Trading Alerts - mfd.ru
Volume Recap: What is the cash position of MoonLake ImmunotherapeuticsWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
Is MoonLake Immunotherapeutics stock heavily shorted2025 Momentum Check & Weekly High Return Opportunities - mfd.ru
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
0.88%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):